 |
36 |
 |
| |
Risk reduction in diabetes: Focus on preclinical disease
|
|
 |
|
 |
|
|
37 |
|
| |
Fatal/nonfatal CHD events in patients with/without history of MI or diabetes
|
|
|
|
|
|
|
38 |
|
| |
↑ Carotid IMT precedes onset of type 2 diabetes
|
|
|
|
|
|
|
39 |
|
| |
Impaired fibrinolytic function in metabolic syndrome
|
|
|
|
|
|
|
40 |
|
| |
NHANES III: Association of metabolic syndrome and chronic kidney disease
|
|
|
|
|
|
|
41 |
|
| |
LIFE: Continuous relation of albuminuria to primary outcome
in patients with diabetes
|
|
|
|
|
|
|
42 |
|
| |
Leukocyte Ang II: Evidence for association with insulin resistance
|
|
|
|
|
|
|
43 |
|
| |
Prediabetic states: Links to subclinical atherosclerosis
|
|
|
|
|
|
|
44 |
|
| |
Increased RAAS activity in diabetic nephropathy
|
|
|
|
|
|
|
45 |
|
| |
NF- kB activation in diabetic nephropathy
|
|
|
|
|
|
|
46 |
|
| |
Glucose activates renal RAAS in concentration-dependent manner
|
|
|
|
|
|
|
47 |
|
| |
HOPE: Risk reduction is independent of diabetes or renal insufficiency
|
|
|
|
|
|
|
48 |
|
| |
Effect of ARBs in patients with type 2 diabetes and nephropathy
|
|
|
|
|
|
|
49 |
|
| |
IDNT: Effect of ARB on CV outcomes
|
|
|
|
|
|
|
50 |
|
| |
LIFE: Comparison of treatment effects in overall population
vs patients with diabetes
|
|
|
|
|
|
|
51 |
|
| |
RAAS and diabetic nephropathy: Proposed mechanisms
|
|
|
|
|
|
|
52 |
|
| |
Antihypertensive agents and risk of diabetes
|
|
|
|
|
|
|
53 |
|
| |
HOPE/HOPE-TOO: Prevention of diabetes
|
|
|
|
|
|
Resources
